The role of methotrexate in osteosarcoma

Jean L. Grem, Susan A. King, Robert E. Wittes, Brian Leyland-jones

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

Original languageEnglish (US)
Pages (from-to)626-655
Number of pages30
JournalJournal of the National Cancer Institute
Issue number9
StatePublished - Jul 6 1988
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'The role of methotrexate in osteosarcoma'. Together they form a unique fingerprint.

Cite this